(BLUE) - Earnings & Price History

BLUE: - 79.55, $3.23B, -0.80 (-1.00%)

Sector: Healthcare - Industry: Biotechnology

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its product candidates include Lenti-D, which is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The companys lead chimeric antigen receptor T cell-based product candidate is bb2121, which is in phase I clinical trials for the treatment of relapsed and refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; an

Past BLUE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2014-11-13Bluebird Bio-0.52-0.6139.1441.2341.1938.641.6-0.10%-4.98%-5.07%367.00K
2014-08-13Bluebird Bio-0.45-0.0635.1134.9434.934.5535.26-0.11%0.60%0.49%281.80K
2014-06-04Bluebird Bio-0.32-0.4422.5822.3722.3922.1522.710.09%▲0.85%0.94%83.40K
2014-03-06Bluebird Bio-0.3-0.3425.9524.124.2123.2526.210.46%7.19%7.68%385.50K
2013-11-13Bluebird Bio-0.2-0.2620.0220.5919.3719.3721.48-5.93%3.36%-2.77%141.00K

Login | Register
Wednesday May 24, 2017   EST
Enter a Ticker:

Economic Calendar

MBA Mortgage Applications 7:00 AM ET FHFA House Price Index 9:00 AM ET Existing Home Sales 10:00 AM ET EIA Petroleum Status Report 10:30 AM ET 2-Yr FRN Note Auction 11:30 AM ET 5-Yr Note Auction 1:00 PM ET FOMC Minutes 2:00 PM ET Robert Kaplan Speaks 6:00 PM ET Neel Kashkari Speaks 6:30 PM ET Charles Evans Speaks 9:25 PM ET  

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color